Torzewski M, Sarbia M, Verreet P, Dutkowski P, Heep H, Willers R, Gabbert H E
Departments of Pathology and Surgery, Heinrich Heine University, 40225 Düsseldorf, Germany.
Clin Cancer Res. 1997 Dec;3(12 Pt 1):2263-8.
In the present study, urokinase-type plasminogen activator (uPA) expression in 150 potentially curatively resected SCCs of the esophagus was analyzed immunohistochemically by means of a murine monoclonal antibody (American Diagnostica, Greenwich, CT) and correlated with survival. Altogether, 122 of the 150 tumors (81.3%) expressed different levels of uPA. Among the 122 uPA-positive tumors, 104 (85.2%) showed a weak staining intensity, and 18 (14.8%) showed a strong staining intensity. Among the uPA-positive tumors, 29 (23. 8%) tumors showed a uPA immunoreactivity in 6-25% of all tumor cells, 30 (24.6%) showed a uPA immunoreactivity in 26-50% of all tumor cells, 41 (33.6%) showed a uPA immunoreactivity in 51-75% of all tumor cells, and 22 (18.0%) showed a uPA immunoreactivity in 76-100% of all tumor cells. No significant correlation could be shown between the different patterns of uPA expression and various clinicopathological parameters, such as pT category, pN category, tumor size, histological grade, blood vessel invasion, lymphatic vessel invasion, and inflammatory response. Concerning the overall postoperative survival, no significant differences between uPA-positive and uPA-negative tumors could be verified. This also held true when different cut points in the percentage of uPA-positive tumor cells were used. In contrast, the intensity of uPA staining provided significant prognostic information in that patients with strongly uPA-positive tumors had a poorer outcome than patients with weakly uPA-positive or uPA-negative tumors. Moreover, as shown by stepwise multivariate Cox regression analysis, the intensity of uPA expression was an independent prognostic factor.
在本研究中，采用鼠单克隆抗体（美国诊断公司，格林威治，康涅狄格州）通过免疫组织化学方法分析了150例可能行根治性切除的食管鳞状细胞癌（SCC）中尿激酶型纤溶酶原激活剂（uPA）的表达情况，并将其与生存率相关联。总共150例肿瘤中有122例（81.3%）表达了不同水平的uPA。在122例uPA阳性肿瘤中，104例（85.2%）染色强度较弱，18例（14.8%）染色强度较强。在uPA阳性肿瘤中，29例（23.8%）肿瘤在所有肿瘤细胞的6% - 25%中显示uPA免疫反应性，30例（24.6%）在所有肿瘤细胞的26% - 50%中显示uPA免疫反应性，41例（33.6%）在所有肿瘤细胞的51% - 75%中显示uPA免疫反应性，22例（18.0%）在所有肿瘤细胞的76% - 100%中显示uPA免疫反应性。uPA表达的不同模式与各种临床病理参数，如pT分期、pN分期、肿瘤大小、组织学分级、血管侵犯、淋巴管侵犯和炎症反应之间未显示出显著相关性。关于总体术后生存率，uPA阳性和uPA阴性肿瘤之间未证实有显著差异。当使用uPA阳性肿瘤细胞百分比的不同切点时，情况也是如此。相比之下，uPA染色强度提供了显著的预后信息，即uPA强阳性肿瘤患者的预后比uPA弱阳性或uPA阴性肿瘤患者差。此外，逐步多因素Cox回归分析表明，uPA表达强度是一个独立的预后因素。
